Details of the Drug Reposition

General Information of This Drug (ID: DMXBLMP)

Drug Name
Riociguat   DMXBLMP
Synonyms
Riociguat; 625115-55-1; Adempas; Riociguat (BAY 63-2521); BAY 63-2521; riociguatum; UNII-RU3FE2Y4XI; RU3FE2Y4XI; CHEBI:76018; Methyl (4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)(methyl)carbamate; Methyl N-(4,6-diamino-2-{1-((2-fluorophenyl)methyl)-1H-pyrazolo(3,4-b)pyridin-3-yl}pyrimidin-5-yl)-N-methylcarbamate; N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methylcarbamic acid methyl ester
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Chronic thromboembolic pulmonary hypertension DISGQ2EA N.A. Approved [1]
------------------------------------------------------------------------------------
1 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Pulmonary arterial hypertension DISP8ZX5 BB01.0 Discontinued in Phase 3 [2]
------------------------------------------------------------------------------------

References

1 Riociguat FDA Label
2 Plasma Exchange for Renal Vasculitis